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removed the next morning. After I had recovered
from the anaesthetic the house officer came to tell
me that while I had been anaesthetised the senior
registrar had in fact examined me internally. I was
furious at this.
I am fortunate to have had enough support to
recover from the hell of being abused. But even
being able to articulate my needs was not sufficient
to protect me from further abuse. How much
worse it must be for those who haven't been as
fortunate as I in recovering from such trauma.
I write because I wish to bring this to the
attention of the medical profession. I have seen
many doctors who, sadly, lack sensitivity in deal-
ing with this issue. Since internal examinations are
common it is important that doctors respect the
needs of those who may require particularly sensi-
tive handling. Maybe much could be learnt from
my experience, which did go badly wrong.
1 Campling P. Working with adult survivors of child sexual abuse.
BMY 1992;305:1375-6. (5 December.)
EDIroR,-I was heartened by the sensitivity of
Penelope Campling's editorial on working with
adult survivors of child sexual abuse.' Even though
child abuse-mainly the sexual variety-has been
a more open subject in the past few years, I have
not seen many articles of this nature in professional
magazines.
Though not wishing to detract from Campling's
writing, I wish to point out that many of the
reactions, feelings, and transferences that she
mentions also apply to those who were not sexually
abused but "only" emotionally abused. The sexual
act does violate the child, but the real damage is
done to the psyche, wherein lies the trauma-
the memory, the damage to self esteem. Similar
damage is done by repeated emotional abuse, and I
believe that the true damage done by this is only
beginning to be seen. Repeated put downs, rejec-
tions, and criticism can produce the same feelings
of confusion, fear of all authority figures, guilt, low
self esteem, seeking for love, and other reactions
listed by Campling.
Doctors who diagnose child sexual abuse from
their observations of a patient may -be wrong.
Sexual abuse may not be the abuse that took place.
Emotional abuse may be the underlying trauma
(and this often comes with a fear of being physic-
ally harmed). As an adult survivor of both types of
abuse and a professional dealing with others
coming to terms with their abuse, I know. I am
delighted to see people like Campling dealing with
this subject with such caring.
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Bronchospasm during
disulfiram-ethanol test reaction
EDrrOR,-We would like to add some comments to
the case report of E Zapata and A Orwin dealing
with bronchoconstriction and hypertension
experienced by a 45 year old man taking alcohol
and disulfiram.'
We investigated the role of acetaldehyde in
causing respiratory distress in subjects with im-
paired hepatic acetaldehyde dehydrogenase activ-
ity or receiving treatment with disulfiram by giving
alcohol to guinea pigs.2 Intravenous administration
of acetaldehyde elicited a prompt rise in blood
pressure and increase in bronchial resistance
associated with augmentation of blood histamine
concentration. Antihistaminic agents significantly
antagonise acetaldehyde actions. Furthermore, we
established that captopril, a well known angio-
tensin converting enzyme inhibitor, strikingly
potentiates the effect of acetaldehyde. Thus, since
the administration of NK2 tachykinin receptor
antagonist reduced the response of the airways to
acetaldehyde in animals pretreated with the angio-
tensin converting enzyme inhibitor, a contribution
of neuropeptides to acetaldehyde activity was
considered a critical point. Unexpectedly, the
infusion of very low doses of acetaldehyde induced
hyperresponsiveness of bronchial smooth muscle
to substance P. Acetaldehyde is clearly able
to interfere with complex neural and humoral
mechanisms regulating the bronchomotor and
cardiovascular functions.
These findings in guinea pigs may have implica-
tions for human respiratory pathology. Robuschi
et al showed that aerosol challenge of asthmatic
patients with acetaldehyde caused a consistent
reduction in forced expiratory volume in one
second.3 Thus it is reasonable to presume that
asthmatic patients, particularly those treated with
angiotensin converting enzyme inhibitors, may
face exacerbation of broncho-obstructive symp-
toms on taking alcohol and its conversion to
acetaldehyde. Furthermore, in patients with a
genetic disposition or pathological alterations
characterised by a reduced aldehyde dehydrogen-
ase activity 47 the repeated alcohol intake, through
the mechanism here described, may result in
bronchial hyperresponsiveness and haemo-
dynamic alterations.
More information will put into correct perspec-
tive, in conjunction with the known pathogenetic
factors (allergic, inflammatory, infectious), the
contribution of alcohol intake to the multifactorial
pathogenesis ofbronchial asthma.
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Monitoring cyclosporin
treatment
ED1TOR,-D J M Reynolds and J K Aronson
provide a clear approach to monitoring cyclosporin
treatment after organ transplantation.' Although
they acknowledge the use of this potent immuno-
modulator in other diseases, however, they fail
to emphasise the differences in monitoring cyclo-
sporin treatment in autoimmune diseases.
As a second line agent cyclosporin is a relatively
new drug in rheumatoid arthritis. Generally, lower
doses are used than in organ transplantation.
Most rheumatologists agree that monitoring the
treatment in rheumatoid disease does not routinely
require measurement of blood cyclosporin con-
centrations2 3: patients' blood pressure, renal
biochemical variables, creatinine clearance, and
full blood count are monitored. Patients with
rheumatoid disease are particularly susceptible to
nephrotoxicity.4 A rise in creatinine (< 30% above
the baseline value) is acceptable and, indeed,
expected.5 Cyclosporin concentrations are checked
only in those patients who are receiving additional
treatments that may have an appreciable interac-
tion with the immunosuppressant.
Cyclosporin is becoming increasingly important
in the management of a wide variety of diseases;
monitoring of the drug will vary according to the
underlying disorder.
C SPEED
Rheumatology Directorate,
South Tees Acute Hospitals NHS Trust,
South Cleveland Hospital,
Middlesbrough,
Cleveland TS4 3BW
1 Reynolds DJM, Aronson JK. Cyclosporin. BMJ 1992;305:
1491-4. (12 December.)
2 Dijkmans BAC, Van Rijthoven AWAM, Goeithe HS, Boeis M,
Cats A. Cyclosporine in rheumatoid arthritis. Semin Arthritis
Rheum 1992;22:30-6.
3 Dougados M, Amor B. Cyclosporin A in rheumatoid arthritis:
preliminary clinical results of an open trial. Arthritis Rheum
1987;30:83-7.
4 Ludwin D, Bennett KJ, Grace EM. Nephrotoxicity in patients
with rheumatoid arthritis treated with cyclosporine. Transplant
Proc 1988;XX(suppl 4):367-70.
5 Tbomson AW, Neild GH. Cyclosporin: use of outside trans-
plantation. BMJ 1991;302:4-5.
Treating hypertension in elderly
patients
EDrroR,-I agree with Kevin O'Malley and Eoin
O'Brien that "a cautious approach to implementing
the results of recent landmark studies may be
wise."' The authors declare that the consistency
across a range of interventional studies in the past
decade is impressive. On the contrary, the consis-
tency is virtually non-existent, except that all
interventions seemed to do some good, but not the
same good, and all but one had no significant effect
on overall mortality.
An Australian trial of treatment of mild hyper-
tension in elderly people showed no reduction in
fatal strokes but a 75% reduction in ischaemic
cardiac deaths.2 In the double blind component of
the study by the European working party on high
blood pressure in the elderly there was an appar-
ently impressive but barely significant reduction in
cardiac deaths (-47%, p=0048).' The authors
reported "a non-significant decrease in cerebro-
vascular death"-that is, no significant reduction
in cerebrovascular death.
In contrast, Coope and Warrender reported a
50% reduction in total strokes, but the "incidence
of myocardial infarction was unaffected by treat-
ment."4 At the end of the five year systolic
hypertension in the elderly trial there was a
reduction in total stroke incidence of 6 per 1000
patient years oftreatment.' There was no significant
reduction in deaths from myocardial infarction. In
the Swedish trial in old patients with hypertension
the reduction in overall mortality was largely due
to a reduction in mortality from stroke.6 There was
no effect on fatal or non-fatal myocardial infarction.
The recently published Medical Research Council
trial showed a reduction in strokes but no signifi-
cant reduction in coronary events.7
If treatment was applied to the generality of
elderly people with hypertension these conflicting
trial results suggest four possible outcomes. Firstly,
cardiac death would be reduced but not death due
to stroke. Secondly, death due to stroke would be
reduced but not cardiac death. Thirdly, both
cardiac death and death due to stroke would be
reduced, but the near universal absence of a fall in
reported overall mortality makes this unlikely.
Fourthly, neither death due to stroke nor cardiac
death would be reduced. On this basis I suggest
that there remains a great deal ofdoubt that mild to
moderate hypertension in elderly people should be
treated.
In elderly people in industrialised societies the
prevalence of arterial hypertension approaches or
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